Anti-PCSK9

Anti-PCSK9
Item number Size Datasheet Manual SDS Delivery time Quantity Price
NSJ-F52952-0.08ML 80 µl - -

3 - 10 business days*

326.00€
NSJ-F52952-0.4ML 400 µl - -

3 - 10 business days*

702.00€
 
In 1X PBS, pH 7.4, with 0.09% sodium azide. Crucial player in the regulation of plasma... more
Product information "Anti-PCSK9"
In 1X PBS, pH 7.4, with 0.09% sodium azide. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Protein function: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non- acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)- mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. [The UniProt Consortium]
Keywords: Anti-PC9, Anti-PCSK9, Anti-NARC1, Anti-NARC-1, Anti-PSEC0052, EC=3.4.21.-, Anti-Proprotein convertase 9, Anti-Subtilisin/kexin-like protease PC9, Anti-Neural apoptosis-regulated convertase 1, Anti-Proprotein convertase subtilisin/kexin type 9, PCSK9 Antib
Supplier: NSJ Bioreagents
Supplier-Nr: F52952

Properties

Application: WB, ELISA
Antibody Type: Polyclonal
Conjugate: No
Host: Rabbit
Species reactivity: human
Immunogen: This PCSK9 antibody was produced from a rabbit immunized with a KLH conjugated synthetic peptide between 654-688 amino acids from the C-terminal region of human PCSK9.
Format: Purified

Handling & Safety

Storage: -20°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Anti-PCSK9"
Write a review
or to review a product.
Viewed